<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1399">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01979419</url>
  </required_header>
  <id_info>
    <org_study_id>HI12C0713</org_study_id>
    <nct_id>NCT01979419</nct_id>
  </id_info>
  <brief_title>Korea Alzheimer's Disease Neuroimaging Initiative</brief_title>
  <acronym>K-ADNI</acronym>
  <official_title>Korea Alzheimer's Disease Neuroimaging Initiative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Alzheimers' Disease Neuroimaing Intitiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean Alzheimers' Disease Neuroimaing Intitiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY OBJECTIVES&#xD;
&#xD;
      -Establish a registry for Alzheimer's disease (AD) and subcortical ischemic vascular dementia&#xD;
      (SIVD)&#xD;
&#xD;
      STUDY DESIGN&#xD;
&#xD;
      -This is a non-randomized, natural history, observational, registry study.&#xD;
&#xD;
      SAMPLE SIZE AND RECRUITMENT&#xD;
&#xD;
      - Five hundred subjects will be enrolled at each clinical site (50 NC, 200 with MCI, 50 with&#xD;
      AD, 100 with vMCI, and 100 with SIVD)&#xD;
&#xD;
      SUMMARY OF KEY ELIGIBILITY CRITERIA&#xD;
&#xD;
        -  Newly enrolled subjects will be between 50-80 (inclusive) years of age.&#xD;
&#xD;
        -  1) Cognitively Normal Subjects&#xD;
&#xD;
        -  2) MCI subjects&#xD;
&#xD;
        -  3) AD subjects&#xD;
&#xD;
        -  4) vMCI or SIVD&#xD;
&#xD;
      PROCEDURES&#xD;
&#xD;
        -  Recruited subjects will have clinical/cognitive assessments, biomarker and genetic&#xD;
           sample collection, and imaging.&#xD;
&#xD;
        -  Subjects will be followed up for 36 months from the baseline visit. All assessments are&#xD;
           to be performed every year from baseline(0, 12, 24, 36 months), except; 1) FDG-PET and&#xD;
           amyloid-PET will be performed every two years, i.e., on baseline and at 24 month visit.&#xD;
           2) CSF collection will also be performed on baseline and at 24 months visit. 3)&#xD;
           Clinical/cognitive assessment and MRI evaluation will additionally be done at 6 months&#xD;
           from baseline to determine short term change.&#xD;
&#xD;
      OUTCOME MEASURES&#xD;
&#xD;
        -  Group differences for each clinical, cognitive, biochemical, and imaging measurement.&#xD;
&#xD;
        -  Rate of conversion or change of disease severity will be evaluated among all groups&#xD;
&#xD;
        -  Correlations among biomarkers and biomarker changes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major goals of K-ADNI are to:&#xD;
&#xD;
        1. Establish a registry for Alzheimer's disease (AD) and subcortical ischemic vascular&#xD;
           dementia (SIVD)&#xD;
&#xD;
             -  Collect longitudinal clinical, imaging, genetic, and biochemical biomarker data for&#xD;
                clinical and neuroscience studies on 500 subjects in five diagnostic categories:&#xD;
                cognitively normal control (NC), mild cognitive impairment (MCI), mild AD, vascular&#xD;
                MCI (vMCI), and SIVD.&#xD;
&#xD;
             -  The following measurements known as representative parameters of dementia progress&#xD;
                will be included. 1) clinical characteristics, 2) neuropsychological test, 3)&#xD;
                structural and functional magnetic resonance image (MRI), 4) Fludeoxyglucose&#xD;
                (FDG)-positron emission tomography (PET), 5) amyloid PET (18F-flutemetamol), 6)&#xD;
                cerebrospinal fluid (CSF) and blood sample, 7) genetic analysis.&#xD;
&#xD;
        2. Determination of factors that are crucial in the aggravation or deterrence of progress&#xD;
           of dementia syndrome, so that these factors can be used as predictors and outcome&#xD;
           measures of AD and SIVD&#xD;
&#xD;
             -  Determine the relationships among clinical, imaging, genetic, and biochemical&#xD;
                biomarker characteristics of the entire spectrum of AD, as the pathology evolves&#xD;
                from normal aging through very mild symptoms, to MCI, and finally to dementia.&#xD;
&#xD;
             -  Also, determine the relationship among clinical, imaging, genetic, and biochemical&#xD;
                biomarker characteristics of the vascular MCI (vMCI) and SIVD, which is an&#xD;
                important sub-population of dementia syndrome especially in Asian population.&#xD;
&#xD;
        3. Identification of surrogate markers for new drug development in patients with AD and&#xD;
           SIVD&#xD;
&#xD;
           - Identify prognostic markers of AD and SIVD, identify outcome measures that can be used&#xD;
           in clinical trials, and help develop the most effective clinical trial scenarios for new&#xD;
           drugs.&#xD;
&#xD;
        4. Development of the standard model for acquiring multi-site neuroimaging study data -&#xD;
           Develop improved methods which will lead to uniform standards for acquiring longitudinal&#xD;
           multi-site clinical, MRI, PET, and other biological markers (blood, CSF, gene) data on&#xD;
           patients with AD, MCI, vMCI, SIVD, and elderly controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Rate of dementia conversion or disease severity worsening, evaluated by neuropsychological, MRI, PET, biomarker indices.</measure>
    <time_frame>0 Months (Baseline), 6 Mos, 12 Mos, 24 Mos, 36 Mos</time_frame>
    <description>- The rate of decline as measured by clinical dementia rating (CDR) Sum of Boxes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cognitive, neuroimaging, and biomarker assessments</measure>
    <time_frame>0 Months (baseline), 6 Mos, 12 Mos, 24 Mos, 36 Mos</time_frame>
    <description>The rate of decline as measured by cognitive tests, Activities of Daily Living&#xD;
The rate of volume change of the whole brain, hippocampus, and other structural MRI measures&#xD;
Rates of change of glucose metabolism (FDG-PET)&#xD;
Extent of amyloid deposition as measured by 18F-flutemetamol&#xD;
Correlations among biomarkers and biomarker changes&#xD;
Group differences for each imaging and biomarker measurement</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer's Disease</condition>
  <condition>Subcortical Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>cognitively normal</arm_group_label>
    <description>MRI scans, PET scans, lumbar puncture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mild cognitive impairment</arm_group_label>
    <description>MRI scans, PET scans, lumbar puncture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
    <description>MRI scans, PET scans, lumbar puncture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vascular MCI</arm_group_label>
    <description>MRI scans, PET scans, lumbar puncture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcortical ischemic vascular dementia</arm_group_label>
    <description>MRI scans, PET scans, lumbar puncture</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Serum, CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cognitively Normal Subjects&#xD;
&#xD;
               -  Mini-Mental State Examination (MMSE) scores between 24-30 (inclusive)&#xD;
&#xD;
               -  Clinical Dementia Rating (CDR)=0&#xD;
&#xD;
               -  non-depressed (Geriatric Depression Scale scores less than 4)&#xD;
&#xD;
               -  no evidence of cognitive impairment&#xD;
&#xD;
          2. MCI subjects&#xD;
&#xD;
               -  MMSE scores between 24-30 (inclusive)&#xD;
&#xD;
               -  a subjective memory concern reported by subject, informant, or clinician&#xD;
&#xD;
               -  objective memory loss measured by age and education year adjusted scores on&#xD;
                  logical memory sub-test (below -1.5 SD)&#xD;
&#xD;
               -  CDR=0.5&#xD;
&#xD;
               -  preserved activities of daily living, and an absence of dementia.&#xD;
&#xD;
          3. AD subjects&#xD;
&#xD;
               -  MMSE scores between 20-26 (inclusive)&#xD;
&#xD;
               -  CDR= 0.5 or 1.0.&#xD;
&#xD;
               -  meets National Institute of Neurological and Communicative Disorders and Stroke /&#xD;
                  Alzheimer's Disease and Related Disorders Associations (NINCDS/ADRDA) criteria&#xD;
                  for probable AD&#xD;
&#xD;
          4. vMCI or SIVD&#xD;
&#xD;
               -  For diagnosis of vMCI or SIVD, it is necessary to meet the above&#xD;
                  clinical/cognitive test scores of MCI or AD.&#xD;
&#xD;
               -  Presence of vascularity are determined by; 1) more than 2 vascular risk factors&#xD;
                  in recent 5 years (hypertension, diabetes, stroke, dyslipidemia, other&#xD;
                  cardiovascular disease, obesity, lack of exercise, and smoking) AND 2) more than&#xD;
                  1 evidence of vascular neurological symptom, sign, or history AND 3) neuroimaging&#xD;
                  evidence of white matter hyperintensity, which is rated moderate or severe on MR&#xD;
                  T2-weighted image(T2WI) or FLAIR images.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Screening/baseline MRI scan with evidence of infection, infarction, or other focal&#xD;
             lesions; Participants with multiple lacunes or lacunes in a critical memory structure&#xD;
             are excluded&#xD;
&#xD;
          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal&#xD;
             fragments or foreign objects in the eyes, skin or body&#xD;
&#xD;
          -  Major depression, bipolar disorder as described in Diagnostic and Statistical Manual&#xD;
             of Mental Disorders, Fourth Edition (DSM-IV) within the past 1 year&#xD;
&#xD;
          -  Currently treated with medication for obsessive-compulsive disorder or attention&#xD;
             deficit disorder&#xD;
&#xD;
          -  History of schizophrenia&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past 2 years&#xD;
&#xD;
          -  Any significant systemic illness or unstable medical condition which could lead to&#xD;
             difficulty complying with the protocol&#xD;
&#xD;
          -  Any significant neurologic disease such as Parkinson's disease, multi-infarct&#xD;
             dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor,&#xD;
             progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple&#xD;
             sclerosis, or history of significant head trauma followed by persistent neurologic&#xD;
             defaults or known structural brain abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong Yoon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center, Univ. of Ulsan, Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seong Yoon Kim</name>
      <address>
        <city>Seoul</city>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korean Alzheimers' Disease Neuroimaing Intitiative</investigator_affiliation>
    <investigator_full_name>Seong Yoon Kim, MD, PhD</investigator_full_name>
    <investigator_title>Professor, Department of Psychiatry, Asan Medical Center</investigator_title>
  </responsible_party>
  <keyword>mild cognitive impairment</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>subcortical Vascular Dementia</keyword>
  <keyword>amyloid</keyword>
  <keyword>plaques</keyword>
  <keyword>neuroimaging</keyword>
  <keyword>biomarkers</keyword>
  <keyword>cognition disorder</keyword>
  <keyword>early detection</keyword>
  <keyword>pre-dementia</keyword>
  <keyword>dementia</keyword>
  <keyword>vascular MCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

